PFE · 10-Q · 2026Q2 · Full report

Acquisition / Partnership / Divestiture

PFIZER INC · 2026-08-04 · Importance 59 · Surprise 60 · In source text

In May 2026, Pfizer entered a global licensing and collaboration agreement with Innovent, a Chinese biopharmaceutical company, covering research and development of 12 early-stage and de novo cancer medicines. Innovent received a $650 million upfront payment and is eligible for up to $9.85 billion in development, regulatory and commercial milestones, plus up to double-digit royalties on approved-product sales. The transaction closed on July 10, 2026, and Pfizer and Innovent will share profits in the U.S., U.K. and European Union for four co-developed and co-commercialized programs.

Key facts

• Pfizer entered into a collaboration agreement with Innovent in May 2026; Innovent received a $650 million upfront payment and is eligible for up to $9.85 billion in milestone payments; Innovent will receive up to double-digit royalties; transaction closed on July 10, 2026. source
• On March 31, 2026, Pfizer completed the exit of its 11.7% investment in ViiV and received $1.875 billion in cash proceeds. source
• Metsera acquisition: Pfizer expects to generate approximately $600 million of annual cost synergies to be achieved by the end of 2026, with one-time costs to generate these synergies expected to be approximately $700 million incurred primarily from 2025 through 2027. source
• For the second quarter and first six months of 2026, the total Other (income)/deductions—net adjustments of $1.0 billion and $850 million, respectively, primarily include: (i) a net gain of $1.870 billion for the second quarter and the first six months from the sale of our previous investment in ViiV, partially offset by (ii) charges of $867 million for the second quarter and $1.0 billion for the first six months for certain legal matters. source
• The change in investing activities was driven mainly by non-recurrence of $6.3 billion proceeds from the sale of the remaining portion of our previous investment in Haleon, partially offset by $1.9 billion proceeds from the sale of our investment in ViiV. source
• Acquisition-related items recorded in cost of sales, selling and other lines for the three months ended June 28, 2026 include amounts of $(336) million, $(4) million and $(250) million respectively (pre-tax). source

Impact estimates